WO2006065555A2 - Use of alpha-adrenergic blockers for the treatment of dysmenorrhea - Google Patents

Use of alpha-adrenergic blockers for the treatment of dysmenorrhea Download PDF

Info

Publication number
WO2006065555A2
WO2006065555A2 PCT/US2005/043657 US2005043657W WO2006065555A2 WO 2006065555 A2 WO2006065555 A2 WO 2006065555A2 US 2005043657 W US2005043657 W US 2005043657W WO 2006065555 A2 WO2006065555 A2 WO 2006065555A2
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
tamsulosin
dysmenorrhea
adrenergic blocker
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/043657
Other languages
French (fr)
Other versions
WO2006065555A3 (en
Inventor
Giora Davidai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharmaceuticals Inc
Priority to EP05852774A priority Critical patent/EP1827404A2/en
Priority to CA002588017A priority patent/CA2588017A1/en
Priority to JP2007546726A priority patent/JP2008523143A/en
Publication of WO2006065555A2 publication Critical patent/WO2006065555A2/en
Publication of WO2006065555A3 publication Critical patent/WO2006065555A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Definitions

  • the present invention relates to a method for the treatment of dysmenorrhea wherein an alpha- adrenergic blocker is administered.
  • Dysmenorrhea is a condition characterized by cyclic pelvic pain or cramping associated with menstruation. Variable in intensity and chronicity, the pain radiates throughout the abdominal and pelvic regions. It is at times associated with systemic symptoms like nausea, vomiting, diarrhea, headaches, fatigue, nervousness, dizziness, and syncope. Primary dysmenorrhea is said to exist when secondary dysmenorrhea, due to underlying pathology, has been excluded.
  • At least one source has reported that approximately 40% of adult females have menstrual pain and that 10% are incapacitated for 1-3 days each month.
  • Primary dysmenorrhea is reported to be a leading cause of workplace absenteeism for women younger than 30 years. Thus, it is clear that dysmenorrhea is a significant medical problem, one which for many women warrants treatment.
  • Dysmenorrhea is most commonly treated with non-steroidal antiinflammatories, which antagonize the effects of prostaglandin, and hormonal contraceptives which interrupt the chronic menstrual related elevation of prostaglandin levels.
  • non-steroidal antiinflammatories which antagonize the effects of prostaglandin
  • hormonal contraceptives which interrupt the chronic menstrual related elevation of prostaglandin levels.
  • both of these treatments are associated with the significant incidence of adverse including gastro-intestinal, renal, hepatic, and cardio-vascular events.
  • More recent studies have been performed evaluating the efficacy and tolerability of various Cox-2 inhibitors and Meloxicam in dysmenorrhea. To date, identification of an efficacious agent with a more favorable tolerability and adverse event profile for dysmenorrhea has not been described.
  • the present invention provides a method for treating primary dysmenorrhea wherein an alpha- adrenergic blocker is administered to a female suffering from the same.
  • primary dysmenorrhea is treated by means of the administration of an alpha-adrenergic blocker (an alpha-adrenoceptor antagonist).
  • an alpha-adrenergic blocker an alpha-adrenoceptor antagonist
  • agents which are not alpha- 1 selective are apt to cause undesirable side-effects (such as postural hypotension, tachycardia, nasal stuffiness and miosis) and because alpha- 1 selective blockade is sufficient for the purpose of treating dysmenorrhea, it is preferred that the agent used be alpha-1 selective (a selective alpha 1 -adrenoceptor antagonist).
  • suitable agents for the practice of the invention would be, for example, the non-selective agent phenoxybenzamine, the partially alpha-1 selective agents alfuzosin, doxazosin, terazosin, prazosin, and the highly selective agent tamsulosin, with the alpha-1 selective agents being preferred.
  • Pharmaceutically acceptable salts or esters of these agents may also be employed.
  • the most preferred agent for the practice of the present invention is tamsulosin or the hydrochloride salt thereof.
  • the alpha blocker be administered via the oral route.
  • Suitable pharmaceutical compositions for the oral administration of the aforementioned agents are known per se.
  • hydrogel- type sustained release pharmaceutical composition in accordance with the teachings of U.S. Patent 6436441 and WOOl 10466 is preferred.
  • the alpha blocker may optionally be co-administered with a Non-Steroidal Anti-Inflammatory Drug (an NSAID).
  • Suitable NSAIDS are, for example, Diclofenac, Difmnisal, Etodolac, Fenoprofen, Floctafenine, Flurbiprofen, Ibuprofen, Indomethacin, Ketoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Nabumetone, Naproxen, Oxaprozin, Phenylbutazone, Piroxicam, Sulindac, Tenoxicam, Tiaprofenic Acid, and Tolmetin. Dosages of these NSAIDS which are suitable for treating dysmenorrhea are well known to those of ordinary skill in the medical art.
  • the NSAID may be administered as a separate dosage form or it may be combined with the alpha blocker into a fixed dose combination.
  • the alpha blocker may optionally be co-administered with the known antispasmodic hyosine-N-butylbromide.
  • the dosage of hyosine-N-butylbromide which is suitable for treating dysmenorrhea is well known to those of ordinary skill in the medical art.
  • the hyosine-N-butylbromide may be administered as a separate dosage form or it may be combined with the alpha blocker into a fixed dose combination.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Use of an alpha-adrenergic blocker for the preparation of a medicament for treating primary dysmenorrhea in a human female suffering from the same. Exemplary alpha-adrenergic blockers are phenoxybenzamine, alfuzosin, doxazosin, terazosin, prazosin, and tamsulsoin, or a pharmaceutically acceptable salt or ester thereof. Tamsulosin HC1 is preferred.

Description

Use of Alpha-adrenergic Blockers for the Treatment of Dysmenorrhea
CROSS-REFERENCE TO RELATED APPLICATIONS
Benefit of U.S. Provisional Application No. 60/635,925, filed on December 13, 2004 and U.S. Provisional Application No. 60/726,506, filed on October 13, 2005 is hereby claimed. BACKGROUND OF THE INVENTION 1. TECHNICAL FIELD
The present invention relates to a method for the treatment of dysmenorrhea wherein an alpha- adrenergic blocker is administered.
2. BACKGROUND INFORMATION
Dysmenorrhea is a condition characterized by cyclic pelvic pain or cramping associated with menstruation. Variable in intensity and chronicity, the pain radiates throughout the abdominal and pelvic regions. It is at times associated with systemic symptoms like nausea, vomiting, diarrhea, headaches, fatigue, nervousness, dizziness, and syncope. Primary dysmenorrhea is said to exist when secondary dysmenorrhea, due to underlying pathology, has been excluded.
Primary dysmenorrhea is believed to be the direct result of increased levels of prostaglandin E-2 and F-2 alpha in the endometrium, the mucous membrane lining the uterus, which occur at menstruation. Elevation of the level of prostaglandin results in vasoconstriction of the small vessels in the uterine wall, which in turn results in increased rhythmic uterine contractions. It is so far unclear whether the discomfort is due to the vasoconstriction, the muscular contractions, or both.
At least one source has reported that approximately 40% of adult females have menstrual pain and that 10% are incapacitated for 1-3 days each month. Primary dysmenorrhea is reported to be a leading cause of workplace absenteeism for women younger than 30 years. Thus, it is clear that dysmenorrhea is a significant medical problem, one which for many women warrants treatment.
Dysmenorrhea is most commonly treated with non-steroidal antiinflammatories, which antagonize the effects of prostaglandin, and hormonal contraceptives which interrupt the chronic menstrual related elevation of prostaglandin levels. Unfortunately, both of these treatments are associated with the significant incidence of adverse including gastro-intestinal, renal, hepatic, and cardio-vascular events. More recent studies have been performed evaluating the efficacy and tolerability of various Cox-2 inhibitors and Meloxicam in dysmenorrhea. To date, identification of an efficacious agent with a more favorable tolerability and adverse event profile for dysmenorrhea has not been described.
While several prior workers have explored the use of alpha-adrenergic blockers for moderating uterine contractions due to pregnancy [Herbert GM et al; Am. J. Obst & Gyn. 139: 767-80, 1981 )] and for treating pre-mature labor [Zupko, I et al; Life Sciences. 61(11): PL 159-163, 1997 and Mihalyi A, et al: Clinical and experimental Pharmacology and Physiology. 30: 164-167, 2003] it appears that the use of alpha-adrenergic blockers for the treatment of dysmenorrhea has never before been proposed.
BRIEF SUMMARY OF THE INVENTION
The present invention provides a method for treating primary dysmenorrhea wherein an alpha- adrenergic blocker is administered to a female suffering from the same.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with the invention, primary dysmenorrhea is treated by means of the administration of an alpha-adrenergic blocker (an alpha-adrenoceptor antagonist).
Because agents which are not alpha- 1 selective are apt to cause undesirable side-effects (such as postural hypotension, tachycardia, nasal stuffiness and miosis) and because alpha- 1 selective blockade is sufficient for the purpose of treating dysmenorrhea, it is preferred that the agent used be alpha-1 selective (a selective alpha 1 -adrenoceptor antagonist).
Thus, suitable agents for the practice of the invention would be, for example, the non-selective agent phenoxybenzamine, the partially alpha-1 selective agents alfuzosin, doxazosin, terazosin, prazosin, and the highly selective agent tamsulosin, with the alpha-1 selective agents being preferred. Pharmaceutically acceptable salts or esters of these agents may also be employed. The most preferred agent for the practice of the present invention is tamsulosin or the hydrochloride salt thereof.
.?- For the purposes of practicing the current invention it is preferred that the alpha blocker be administered via the oral route. Suitable pharmaceutical compositions for the oral administration of the aforementioned agents are known per se.
The preparation of tamsulosin, tamsulosin, pharmaceutically acceptable salts thereof, including in particular the hydrochloride, and pharmaceutical preparations thereof are described in U.S. Patents US 4,703,063 and US 4,772,475.
For the administration of tamsulosin or pharmaceutically acceptable salts thereof, a hydrogel- type sustained release pharmaceutical composition in accordance with the teachings of U.S. Patent 6436441 and WOOl 10466 is preferred.
Suitable dosages for the listed alpha blockers are given in Table 1.
Figure imgf000004_0001
In accordance with the invention, the alpha blocker may optionally be co-administered with a Non-Steroidal Anti-Inflammatory Drug (an NSAID). Suitable NSAIDS are, for example, Diclofenac, Difmnisal, Etodolac, Fenoprofen, Floctafenine, Flurbiprofen, Ibuprofen, Indomethacin, Ketoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Nabumetone, Naproxen, Oxaprozin, Phenylbutazone, Piroxicam, Sulindac, Tenoxicam, Tiaprofenic Acid, and Tolmetin. Dosages of these NSAIDS which are suitable for treating dysmenorrhea are well known to those of ordinary skill in the medical art. The NSAID may be administered as a separate dosage form or it may be combined with the alpha blocker into a fixed dose combination.
Further in accordance with the invention, the alpha blocker may optionally be co-administered with the known antispasmodic hyosine-N-butylbromide. The dosage of hyosine-N-butylbromide which is suitable for treating dysmenorrhea is well known to those of ordinary skill in the medical art. The hyosine-N-butylbromide may be administered as a separate dosage form or it may be combined with the alpha blocker into a fixed dose combination.

Claims

CLAIMS:
I . A method of treating primary dysmenorrhea which comprises administering to a human female suffering from the same a therapeutically effective amount of alpha-adrenergic blocker.
2. The method of claim 1 wherein the alpha-adrenergic blocker is selected from the group consisting of phenoxybenzamine, alfuzosin, doxazosin, terazosin, prazosin, and tamsulosin, or a pharmaceutically acceptable salt or ester thereof.
3. The method of claim 1 wherein the alpha-adrenergic blocker is tamsulosin or a pharmaceutically acceptable salt or ester thereof.
4. The method of claim 3 wherein the alpha-adrenergic blocker is tamsulosin hydrochloride.
5. The method of claim 4, wherein the tamsulosin hydrochloride is administered orally at a dosage of 0.2 - 3.0 mg once per day.
6. The method of claim 5, wherein the tamsulosin hydrochloride which is administered orally at a dosage of 0.8-1.2mg once per day.
7. Use of an alpha-adrenergic blocker for the preparation of a medicament for the treatment of primary dysmenorrhea in a human female.
8. The use of claim 7 wherein the alpha-adrenergic blocker is selected from the group consisting of phenoxybenzamine, alfuzosin, doxazosin, terazosin, prazosin, and tamsulosin, or a pharmaceutically acceptable salt or ester thereof.
9. The use of claim 7 wherein the alpha-adrenergic blocker is tamsulosin or a pharmaceutically acceptable salt or ester thereof.
10. The use of claim 9 wherein the alpha-adrenergic blocker is tamsulosin hydrochloride.
I I. The use of claim 10, wherein the tamsulosin hydrochloride is administered orally at a dosage of 0.4 - 1.6 mg once per day. 12. The use of claim 10, wherein the tamsulosin hydrochloride is administered orally at a dosage of 0.8-1.2mg once per day.
PCT/US2005/043657 2004-12-13 2005-12-02 Use of alpha-adrenergic blockers for the treatment of dysmenorrhea Ceased WO2006065555A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05852774A EP1827404A2 (en) 2004-12-13 2005-12-02 Use of alpha-adrenergic blockers for the treatment of dysmenorrhea
CA002588017A CA2588017A1 (en) 2004-12-13 2005-12-02 Use of alpha-adrenergic blockers for the treatment of dysmenorrhea
JP2007546726A JP2008523143A (en) 2004-12-13 2005-12-02 Use of α-adrenergic blockers for the treatment of dysmenorrhea

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63592504P 2004-12-13 2004-12-13
US60/635,925 2004-12-13
US72650605P 2005-10-13 2005-10-13
US60/726,506 2005-10-13

Publications (2)

Publication Number Publication Date
WO2006065555A2 true WO2006065555A2 (en) 2006-06-22
WO2006065555A3 WO2006065555A3 (en) 2006-08-31

Family

ID=36168388

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/043657 Ceased WO2006065555A2 (en) 2004-12-13 2005-12-02 Use of alpha-adrenergic blockers for the treatment of dysmenorrhea

Country Status (7)

Country Link
US (1) US20060128719A1 (en)
EP (1) EP1827404A2 (en)
JP (1) JP2008523143A (en)
AR (1) AR051791A1 (en)
CA (1) CA2588017A1 (en)
TW (1) TW200633692A (en)
WO (1) WO2006065555A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399241B2 (en) 2004-12-01 2013-03-19 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
US8501465B2 (en) 2007-12-21 2013-08-06 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
US9018003B2 (en) 2005-05-13 2015-04-28 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073388A2 (en) * 2006-12-11 2008-06-19 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making and methods of use
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
EP3041465B1 (en) * 2013-09-06 2020-11-11 The University Of Montana Method of reducing neuronal cell death with haloalkylamines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
JPH06507392A (en) * 1991-02-26 1994-08-25 エイアールシー　１，インコーポレイテッド Compositions and methods for the treatment of sympathetic persistent pain
JP3140465B2 (en) * 1992-09-18 2001-03-05 山之内製薬株式会社 Hydrogel sustained release formulation
CA2272330A1 (en) * 1996-12-06 1998-06-11 Irene Drizin Benzopyranopyrrole and benzopyranopyridine alpha-1 adrenergic compounds
US6133275A (en) * 1998-05-06 2000-10-17 Abbott Laboratories 3-phenylpyrrolidine alpha-1 adrenergic compounds
TW536402B (en) * 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
US6376488B1 (en) * 2000-09-07 2002-04-23 Abbott Laboratories Benzoxazine α-1 adrenergic compounds

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399241B2 (en) 2004-12-01 2013-03-19 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
US10526651B2 (en) 2004-12-01 2020-01-07 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
US9018003B2 (en) 2005-05-13 2015-04-28 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
US9879257B2 (en) 2005-05-13 2018-01-30 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
US8501465B2 (en) 2007-12-21 2013-08-06 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
US9249444B2 (en) 2007-12-21 2016-02-02 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
US9909160B2 (en) 2007-12-21 2018-03-06 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity

Also Published As

Publication number Publication date
AR051791A1 (en) 2007-02-07
TW200633692A (en) 2006-10-01
WO2006065555A3 (en) 2006-08-31
US20060128719A1 (en) 2006-06-15
JP2008523143A (en) 2008-07-03
EP1827404A2 (en) 2007-09-05
CA2588017A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
Corea et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine
Kim et al. The use of corticosteroids and nonsteroidal antiinflammatory medication for the management of pain and inflammation after third molar surgery: a review of the literature
JP5312027B2 (en) Disease treatment
JP2005512995A (en) Antimuscarinic and estrogen agonists for treating unstable or overactive bladder
US20220008415A1 (en) Combination Therapy for Male Sexual Dysfunction
Dahiya et al. Efficacy of combined hormonal vaginal ring in comparison to combined hormonal pills in heavy menstrual bleeding
EP4494701A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
JP2016503803A (en) Transmucosal delivery of glatiramer acetate
NO322079B1 (en) Mixture comprising an alpha-adrenergic antagonist and a dopaminergic agonist.
EA031488B1 (en) Method for treating gynecological diseases
US20060128719A1 (en) Use of alpha-adrenergic blockers for the treatment of dysmenorrhea
US20180125792A1 (en) Non-steroidal anti-inflammatory drugs for cough
CN1108795C (en) Treatment of uterine contractility disorders with nitric oxide synthase substrates and/or donors, or nitric oxide inhibitors
JP2024529084A (en) Methods of Treating Endometriosis and Providing Effective Contraception - Patent application
JPH06506684A (en) Ibuprofen - decongestant formulation
US8871228B2 (en) Injectable composition containing hydroxychloroquine for local administration for treating hemorrhoids
JP3151217B2 (en) Uses of Atipamezole for the treatment of male or male impotence
CZ2004719A3 (en) Medicament containing darifenacin and intended for reducing urgency in patients suffering from overactive bladder
JPWO2005063253A1 (en) Pharmaceutical composition for treatment of allergic symptoms
EA029932B1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
US20100292150A1 (en) Treatment of Menorrhagia with Aromatase Inhibitor
JP2016121090A (en) Medicine for suppressing uterine bleeding in patients with uterine adenomyosis
JP4766818B2 (en) Agents for improving and treating specific back pain, hip joint pain and groin pain during pregnancy
BR122025016695A2 (en) Uses of Drosspirenone, Pharmaceutical Composition and Drosspirenone Kit
Sharma et al. Observational Study

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005852774

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2588017

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007546726

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005852774

Country of ref document: EP